Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.
Identifieur interne : 000799 ( Main/Exploration ); précédent : 000798; suivant : 000800Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.
Auteurs : RBID : pubmed:23564795English descriptors
- KwdEn :
- Animals, Binding, Competitive, CHO Cells, Carcinoma, Pancreatic Ductal (metabolism), Carcinoma, Pancreatic Ductal (radionuclide imaging), Carcinoma, Pancreatic Ductal (radiotherapy), Cells, Cultured, Cricetinae, Drug Design, Female, Heterocyclic Compounds, 1-Ring (chemistry), Humans, Indium Radioisotopes (diagnostic use), Mice, Mice, Inbred BALB C, Mice, Nude, Pancreatic Neoplasms (metabolism), Pancreatic Neoplasms (radionuclide imaging), Pancreatic Neoplasms (radiotherapy), Peptide Fragments (metabolism), Peptide Fragments (pharmacokinetics), Radiopharmaceuticals (diagnostic use), Receptors, Vasoactive Intestinal Peptide (metabolism), Tissue Distribution, Vasoactive Intestinal Peptide (metabolism), Vasoactive Intestinal Peptide (pharmacokinetics).
- MESH :
- chemical , chemistry : Heterocyclic Compounds, 1-Ring.
- chemical , diagnostic use : Indium Radioisotopes, Radiopharmaceuticals.
- metabolism : Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Peptide Fragments, Receptors, Vasoactive Intestinal Peptide, Vasoactive Intestinal Peptide.
- chemical , pharmacokinetics : Peptide Fragments, Vasoactive Intestinal Peptide.
- radionuclide imaging : Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms.
- radiotherapy : Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms.
- Animals, Binding, Competitive, CHO Cells, Cells, Cultured, Cricetinae, Drug Design, Female, Humans, Mice, Mice, Inbred BALB C, Mice, Nude, Tissue Distribution.
Abstract
Vasoactive intestinal peptide (VIP) receptors are overexpressed in a broad variety of tumours. For the detection of these tumours, novel chemically modified and shortened VIP derivatives were designed.
PubMed: 23564795
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.</title><author><name sortKey="Rangger, Christine" uniqKey="Rangger C">Christine Rangger</name><affiliation wicri:level="1"><nlm:affiliation>Clinical Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria.</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Clinical Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck</wicri:regionArea></affiliation></author><author><name sortKey="Helbok, Anna" uniqKey="Helbok A">Anna Helbok</name></author><author><name sortKey="Ocak, Meltem" uniqKey="Ocak M">Meltem Ocak</name></author><author><name sortKey="Radolf, Thorsten" uniqKey="Radolf T">Thorsten Radolf</name></author><author><name sortKey="Andreae, Fritz" uniqKey="Andreae F">Fritz Andreae</name></author><author><name sortKey="Virgolini, Irene J" uniqKey="Virgolini I">Irene J Virgolini</name></author><author><name sortKey="Von Guggenberg, Elisabeth" uniqKey="Von Guggenberg E">Elisabeth Von Guggenberg</name></author><author><name sortKey="Decristoforo, Clemens" uniqKey="Decristoforo C">Clemens Decristoforo</name></author></titleStmt><publicationStmt><date when="2013">2013</date><idno type="RBID">pubmed:23564795</idno><idno type="pmid">23564795</idno><idno type="wicri:Area/Main/Corpus">000696</idno><idno type="wicri:Area/Main/Curation">000696</idno><idno type="wicri:Area/Main/Exploration">000799</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Binding, Competitive</term><term>CHO Cells</term><term>Carcinoma, Pancreatic Ductal (metabolism)</term><term>Carcinoma, Pancreatic Ductal (radionuclide imaging)</term><term>Carcinoma, Pancreatic Ductal (radiotherapy)</term><term>Cells, Cultured</term><term>Cricetinae</term><term>Drug Design</term><term>Female</term><term>Heterocyclic Compounds, 1-Ring (chemistry)</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mice, Nude</term><term>Pancreatic Neoplasms (metabolism)</term><term>Pancreatic Neoplasms (radionuclide imaging)</term><term>Pancreatic Neoplasms (radiotherapy)</term><term>Peptide Fragments (metabolism)</term><term>Peptide Fragments (pharmacokinetics)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Receptors, Vasoactive Intestinal Peptide (metabolism)</term><term>Tissue Distribution</term><term>Vasoactive Intestinal Peptide (metabolism)</term><term>Vasoactive Intestinal Peptide (pharmacokinetics)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Heterocyclic Compounds, 1-Ring</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Indium Radioisotopes</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Carcinoma, Pancreatic Ductal</term><term>Pancreatic Neoplasms</term><term>Peptide Fragments</term><term>Receptors, Vasoactive Intestinal Peptide</term><term>Vasoactive Intestinal Peptide</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Peptide Fragments</term><term>Vasoactive Intestinal Peptide</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma, Pancreatic Ductal</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Carcinoma, Pancreatic Ductal</term><term>Pancreatic Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Binding, Competitive</term><term>CHO Cells</term><term>Cells, Cultured</term><term>Cricetinae</term><term>Drug Design</term><term>Female</term><term>Humans</term><term>Mice</term><term>Mice, Inbred BALB C</term><term>Mice, Nude</term><term>Tissue Distribution</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Vasoactive intestinal peptide (VIP) receptors are overexpressed in a broad variety of tumours. For the detection of these tumours, novel chemically modified and shortened VIP derivatives were designed.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">23564795</PMID><DateCreated><Year>2013</Year><Month>04</Month><Day>08</Day></DateCreated><DateCompleted><Year>2013</Year><Month>06</Month><Day>11</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1791-7530</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Anticancer research</Title><ISOAbbreviation>Anticancer Res.</ISOAbbreviation></Journal><ArticleTitle>Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.</ArticleTitle><Pagination><MedlinePgn>1537-46</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Vasoactive intestinal peptide (VIP) receptors are overexpressed in a broad variety of tumours. For the detection of these tumours, novel chemically modified and shortened VIP derivatives were designed.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)-derivatised VIP analogues were radiolabelled with (111)In and in vitro and in vivo behaviour was evaluated using stability and internalisation assays, as well as an initial biodistribution study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Radiolabelling of the VIP analogues resulted in high radiochemical yields, without need for further purification steps. Stability of the VIP derivatives was variable and cell uptake studies in VIP receptor-positive cell lines revealed that only a limited number of derivatives were internalised. In the tumour mouse model, no specific tumour targeting was shown.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Since the tested VIP derivatives exhibited impaired in vitro and in vivo characteristics alternative modifications to increase their stability while retaining receptor affinity should be considered to enable the use of synthetic VIP analogues for tumour targeting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rangger</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Affiliation>Clinical Department of Nuclear Medicine, Innsbruck Medical University, Innsbruck, Austria.</Affiliation></Author><Author ValidYN="Y"><LastName>Helbok</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Ocak</LastName><ForeName>Meltem</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Radolf</LastName><ForeName>Thorsten</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Andreae</LastName><ForeName>Fritz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Virgolini</LastName><ForeName>Irene J</ForeName><Initials>IJ</Initials></Author><Author ValidYN="Y"><LastName>Von Guggenberg</LastName><ForeName>Elisabeth</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Decristoforo</LastName><ForeName>Clemens</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Evaluation Studies</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Anticancer Res</MedlineTA><NlmUniqueID>8102988</NlmUniqueID><ISSNLinking>0250-7005</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Heterocyclic Compounds, 1-Ring</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Vasoactive Intestinal Peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>37221-79-7</RegistryNumber><NameOfSubstance>Vasoactive Intestinal Peptide</NameOfSubstance></Chemical><Chemical><RegistryNumber>60239-18-1</RegistryNumber><NameOfSubstance>1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Binding, Competitive</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">CHO Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma, Pancreatic Ductal</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cricetinae</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Heterocyclic Compounds, 1-Ring</DescriptorName><QualifierName MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice, Nude</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Pancreatic Neoplasms</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Peptide Fragments</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Vasoactive Intestinal Peptide</DescriptorName><QualifierName MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tissue Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Vasoactive Intestinal Peptide</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="Y">pharmacokinetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">33/4/1537</ArticleId><ArticleId IdType="pubmed">23564795</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000799 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000799 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:23564795
|texte= Design and evaluation of novel radiolabelled VIP derivatives for tumour targeting.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:23564795" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |